Table 1. Baseline patient characteristics.
| Clinical variable | Value, n (%) |
|---|---|
| Age (years) | |
| ≤60 | 31 (52.5) |
| >60 | 28 (47.5) |
| Gender | |
| Male | 32 (54.2) |
| Female | 27 (45.7) |
| Race | |
| Caucasian | 47 (79.7) |
| African-American | 11 (18.6) |
| Other | 1 (1.7) |
| Eastern Cooperative Oncology Group (ECOG) | |
| 0 | 34 (57.6) |
| 1 | 21 (35.6) |
| 2 | 1 (1.7) |
| Unknown | 3 (5.1) |
| Site of primary | |
| Pancreas | 18 (30.5) |
| Foregut | 3 (5.1) |
| Midgut | 16 (27.1) |
| Hindgut | 3 (5.1) |
| Lung | 7 (11.9) |
| Kidney | 1 (1.7) |
| Thymus | 1 (1.7) |
| Unknown | 10 (16.9) |
| Tumor grade | |
| 1 | 23 (39.0) |
| 2 | 22 (37.3) |
| 3 | 8 (13.6) |
| Unknown | 6 (5.1) |
| Carcinoid syndrome | |
| Yes | 22 (37.3) |
| No | 37 (62.6) |
| Extrahepatic metastases | |
| Yes | 21 (35.6) |
| No | 38 (64.4) |
| Resection of primary tumor | |
| Yes | 30 (50.1) |
| No | 29 (49.2) |
| Prior liver-directed therapy | |
| Yes | 16 (27.1) |
| No | 43 (72.9) |
| Type of prior therapy | |
| Surgery | 7 (11.9) |
| Chemoembolization | 5 (8.5) |
| Radiofrequency ablation | 1 (1.7) |
| Bland embolization | 3 (5.1) |
| Prior octreotide | |
| Yes | 45 (76.3) |
| No | 14 (23.7) |
| Prior biologic therapy | |
| Yes | 25 (42.4) |
| No | 34 (57.6) |
| Biologic agent | |
| Bevacizumab | 6 (5.1) |
| Everolimus | 12 (10.2) |
| Sunitinib | 6 (5.1) |
| Pazopanib | 1 (1.7) |
| Prior chemotherapy | |
| Yes | 13 (22.0) |
| No | 46 (78.0) |
| Pre-treatment chromogranin A | |
| ≤500 | 19 (52.8) |
| >500 | 17 (47.2) |
| Tumor volume | |
| ≤200 cc | 25 (46.3) |
| <200 cc | 29 (53.7) |
Data missing in pretreatment Chromogranin A (n=36) and tumor volume (n=54).